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Abstract
Background Optimal management of attention deficit
hyperactivity disorder (ADHD) aims not only to ameliorate
patients’ symptoms, but also to improve health-related
quality of life (HRQL) and functioning. A pivotal, 7-week,
randomized, double-blind, placebo-controlled, phase III
study in children and adolescents in ten European countries
demonstrated that the stimulant prodrug lisdexamfetamine
dimesylate (LDX) is an effective and generally well-tol-
erated treatment for symptoms of ADHD.
Objective The aim of this study was to assess HRQL and
functional impairment outcomes in this clinical trial, using
the Child Health and Illness Profile-Child Edition: Parent
Report Form (CHIP-CE:PRF) and the Weiss Functional
Impairment Rating Scale-Parent Report (WFIRS-P),
respectively.
Methods Patients (aged 6–17 years) with diagnosed
ADHD and a baseline ADHD Rating Scale IV total score
C28 were randomized (1:1:1) to 7 weeks of double-blind
treatment with once-daily LDX, placebo or the reference
treatment, osmotic-release oral system methylphenidate
(OROS-MPH). Participants’ parents (or legally authorized
representatives) completed the CHIP-CE:PRF and WFIRS-
P questionnaires at baseline, at weeks 4 and 7, and/or at
early termination. Endpoint was defined as the last
on-treatment visit with valid data (B30 % missing items).
The CHIP-CE:PRF Achievement domain was pre-specified
as the primary HRQL outcome.
Results The full analysis set comprised 317 patients
(LDX, n = 104; placebo, n = 106; OROS-MPH,
n = 107), the majority of whom completed the study
(LDX, n = 77; placebo, n = 42; OROS-MPH, n = 72).
Baseline CHIP-CE:PRF T-scores in four of the five
domains were C1 standard deviation below norms (US
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community samples). Compared with placebo, LDX was
associated with statistically significantly improved T-scores
from baseline to endpoint in these four domains, with
effect sizes of 1.280 (p \ 0.001) in Achievement, 1.079
(p \ 0.001) in Risk Avoidance, 0.421 (p \ 0.01) in
Resilience and 0.365 (p \ 0.05) in Satisfaction. In LDX-
treated patients, placebo-adjusted improvements from
baseline to endpoint in WFIRS-P scores were statistically
significant (p \ 0.001) for total score and four of the six
domains, with effect sizes of 0.924 (total score), 1.249
(Learning and School), 0.730 (Family), 0.643 (Social
Activities) and 0.640 (Risky Activities). OROS-MPH
treatment showed similar patterns of improvement from
baseline to endpoint in both CHIP-CE:PRF and WFIRS-P
scores.
Conclusions Baseline HRQL and functional impairment
scores reflect the burden of untreated ADHD. The benefits
of short-term stimulant treatment in children and adoles-
cents with ADHD extend beyond symptomatic relief and
impact positively on HRQL and daily functioning.
1 Introduction
Attention deficit hyperactivity disorder (ADHD) is one of
the most prevalent psychiatric disorders of childhood [1]
and is increasingly recognized as a condition that can
persist into adulthood [2, 3]. The International Classifica-
tion of Diseases, 10th Revision (ICD-10) [4], Diagnostic
and Statistical Manual of Mental Disorders, 4th edition,
text revision (DSM-IV-TR) [5] and DSM, 5th edition
(DSM-5) [6] diagnostic criteria for ADHD all require not
only the presence of symptoms, but also evidence of sig-
nificant impairment in social, academic or occupational
functioning. The motivation for seeking medical attention
is typically the impact on an individual’s behaviour in daily
life in domains such as educational achievement and
relations with teachers, family and peers [7]. Therefore, in
addition to symptomatic relief, important goals in the
treatment of ADHD are to improve health-related quality
of life (HRQL) and to reduce functional impairment
[8–10].
European and North American guidelines for the treat-
ment of ADHD in children and adolescents recommend
stimulants as part of a multimodal treatment plan incor-
porating psychoeducational, behavioural and/or other psy-
chosocial interventions [11–18]. Lisdexamfetamine
dimesylate (LDX) is the first and only stimulant prodrug.
Long-acting amfetamine-based medications, including
LDX, are an established front-line treatment option in
North America for children, adolescents and adults with
ADHD. In Europe, LDX is the only long-acting amfeta-
mine-based medication with marketing authorization
(in select countries) for the treatment of ADHD, where it is
indicated in children and adolescents when response to
previous methylphenidate is considered inadequate. A
series of US-based, phase III clinical trials in children
(aged 6–12 years) [19], adolescents (aged 13–17 years)
[20] and adults (aged 18–55 years) [21] demonstrated that
LDX is an effective and generally well-tolerated treatment
for the symptoms of ADHD. Therapeutic benefits in sim-
ulated school or workplace environments were sustained
for at least 13 h in children [22] and 14 h in adults [23]
following an early-morning dose of LDX. More recently, a
pivotal, double-blind, placebo-controlled phase III trial
(study SPD489-325) investigated the efficacy and safety of
LDX in children and adolescents with ADHD in Europe
[24]. In this 7-week study, patients receiving LDX or the
reference treatment (osmotic-release oral system methyl-
phenidate; OROS-MPH) showed statistically significantly
greater improvements in symptoms than those receiving
placebo (p \ 0.001), as assessed using the ADHD Rating
Scale IV (ADHD-RS-IV), with effect sizes of 1.80 and
1.26, respectively (primary efficacy outcome). On the
Clinical Global Impressions-Improvement (CGI-I) scale,
78 % of patients in the LDX group and 61 % of those in
the OROS-MPH group scored 1 (‘very much improved’) or
2 (‘much improved’), compared with 14 % in the placebo
group (p \ 0.001 for both active treatments).
We now report HRQL and functional impairment out-
comes from study SPD489-325, as assessed using the Child
Health and Illness Profile-Child Edition: Parent Report
Form (CHIP-CE:PRF) and the Weiss Functional Impair-
ment Rating Scale-Parent Report (WFIRS-P), respectively.
The CHIP-CE:PRF is a generic, paediatric HRQL instru-
ment with established validity and reliability in ADHD
[25]. It measures overall health status, including emotional
and physical well-being, behaviour, performance and
involvement with family and peers. The WFIRS-P is an
ADHD-specific instrument with demonstrated sensitivity
[26, 27], and addresses domains of daily functioning that
are likely to be impaired in ADHD. Assessing the impact of
LDX compared with placebo on HRQL and functional
impairment were pre-specified secondary objectives of the
study.
2 Methods
The study procedures of this randomized, double-blind,
parallel-group, dose-optimized, placebo-controlled, phase
III trial have been described previously [24]. Study
SPD489-325 (ClinicalTrials.gov identifier: NCT00763971)
was conducted in accordance with current applicable
regulations, the International Conference on Harmonisa-
tion of Good Clinical Practice, local ethical and legal
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requirements, and the Declaration of Helsinki (including its
amendments). The study protocol was approved by an
independent ethics committee/institutional review board
and regulatory agency in each centre (as appropriate)
before study initiation. Each patient’s parent or legal
guardian provided written, informed consent, and assent
was obtained from each participant (as applicable) before
commencing study-related procedures. The study took
place between November 2008 and March 2011 [24].
2.1 Study Population
The study was conducted in 48 centres in ten European
countries, and enrolled male and female children (aged
6–12 years) and adolescents (aged 13–17 years) who met
DSM-IV-TR [5] criteria for a primary diagnosis of ADHD.
Eligible patients had an investigator-rated ADHD-RS-IV
total score of 28 or higher at baseline, indicating symptoms
of at least moderate severity. Key exclusion criteria
included failure to respond to a previous course of OROS-
MPH (but not of other formulations of methylphenidate)
and the presence of a comorbid psychiatric diagnosis with
significant symptoms (not including oppositional defiant
disorder). Patients whose current ADHD medication pro-
vided effective control of symptoms with acceptable tol-
erability were also excluded. Enrolment was stratified such
that adolescents comprised approximately 25 % of the
study population.
2.2 Study Drug Administration
Eligible patients completed a screening and washout period
(up to 6 weeks) and were randomized (1:1:1) to receive
once-daily LDX, placebo or the reference treatment
(OROS-MPH). Randomization was stratified by country
and age group (6–12 years of age or 13–17 years of age).
Details of randomization and blinding have been previ-
ously described [24]. As shown in Fig. 1, the 7-week,
double-blind evaluation period consisted of a 4-week dose-
optimization period (visits 1–3) and a 3-week dose-main-
tenance period (visits 4–7), followed by a 1-week washout
and safety follow-up (visit 8).
Dose optimization to LDX 30, 50 or 70 mg daily, or to
OROS-MPH 18, 36 or 54 mg daily (54 mg being the
maximum OROS-MPH dose approved in Europe) was
based on achieving an ‘acceptable response’, defined as a
reduction of at least 30 % in ADHD-RS-IV total score
from baseline and a CGI-I rating of 1 (‘very much
improved’) or 2 (‘much improved’), with tolerable side
effects. Instructions were that study drugs should be taken
daily upon wakening at approximately 0700 hours, begin-
ning on the day after completion of the baseline visit (visit
0). Patients initially received LDX 30 mg daily, OROS-
MPH 18 mg daily or placebo. If an acceptable response
was not achieved, doses were increased in 20 mg (LDX) or
18 mg (OROS-MPH) steps at weekly intervals. One
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Fig. 1 SPD489-325 study design. aScreening and washout (visit -1)
was conducted up to 6 weeks before baseline visit (week 0). At visits
1–3 (weeks 1–3), doses were titrated in the indicated single steps to
achieve optimal tolerability and efficacy. From visit 4 onwards, doses
could not be altered. Child Health and Illness Profile-Child Edition:
Parent Report Form and Weiss Functional Impairment Rating Scale-
Parent Report assessments were performed at baseline, and then
at visits 4 and 7 (shown boxed) and/or at an early termination
visit attended by patients who discontinued the trial. LDX lis-
dexamfetamine dimesylate, OROS-MPH osmotic-release oral system
methylphenidate
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unacceptable tolerability. After visit 3, the dose could not
be changed: participants unable to tolerate the study drug
after this point were withdrawn from the study and atten-
ded an early termination visit. Patients who achieved an
acceptable response continued on their optimal dose for the
remainder of the double-blind evaluation period (visits
4–7) [Fig. 1].
It should be noted that the reference arm included
OROS-MPH as an active control and not as a comparator.
An active control is an established treatment known to be
superior to placebo. The purpose of the reference arm is to
facilitate interpretation of the study, especially in the case
of an apparently negative outcome in the experimental arm.
The study was neither designed nor statistically powered
for comparison of the test drug with the reference treat-
ment. Although this does not preclude post hoc analysis,
statistical comparisons of LDX with OROS-MPH are not
presented here.
2.3 HRQL Measure: Child Health and Illness
Profile-Child Edition: Parent Report
Form (CHIP-CE:PRF)
The CHIP-CE:PRF questionnaire comprises 76 items
classed into five domains and 12 associated subdomains.
Most items relate to the past 4 weeks; the remainder are not
associated with a specific time period. Parents use a 5-point
response format to assess each item. Data were handled
according to the CHIP-CE Technical Manual [28]. Domain
and subdomain scores were the mean of the appropriate
individual item scores (omitting items with a missing
score). For a domain or subdomain score to be valid, no
more than 30 % of the applicable items could be missing.
The domain and subdomain scores were standardized to
T-scores with a mean of 50 and a standard deviation (SD)
of 10, using an algorithm based on normative sample data
from the US [29]. Higher CHIP-CE:PRF T-scores indicate
better HRQL. The CHIP-CE:PRF Achievement domain
was pre-specified as the primary HRQL measure.
2.4 Functional Measure: Weiss Functional Impairment
Rating Scale-Parent Report (WFIRS-P)
The WFIRS-P questionnaire comprises 50 items grouped
into six domains. The items relate to the past month and are
scored using a 4-point Likert scale: 0 (never or not at all); 1
(sometimes or somewhat); 2 (often or much); or 3 (very
often or very much) [30, 31]. The WFIRS-P domain scores
for each patient were the mean of the items in each domain,
or of all the items for total score, omitting items with a
missing or ‘not applicable’ score. WFIRS-P domain or total
scores were considered invalid if more than 30 % of the
item scores used for calculation were missing or ‘not
applicable’ (with the exception of one question relating to
siblings, for which a score of ‘not applicable’ could con-
tribute to the minimum number of items). Higher WFIRS-P
scores indicate more severe functional impairment.
2.5 Schedule of CHIP-CE:PRF and WFIRS-P
Assessments
A parent (or legally authorized representative) completed
the CHIP-CE:PRF and WFIRS-P questionnaires at baseline
(visit 0), then at visits 4 and 7 (weeks 4 and 7) and/or at
early termination (Fig. 1). Visit 4 (week 4) assessments
were introduced via a protocol amendment after study
initiation and therefore were not conducted for all partici-
pants. Endpoint was defined as the last on-treatment visit
(including early termination) at which a valid CHIP-
CE:PRF domain or subdomain score, or valid WFIRS-P
domain or total score, was obtained.
2.6 Statistical Analyses
All analyses were based on the full analysis set, defined as
patients who were randomized and took at least one dose of
study drug, but excluding patients from one site (n = 15)
where there were violations of good clinical practice.
Sample sizes were determined as previously described
[24]. To assess statistically the effect of treatment with
either LDX or OROS-MPH versus placebo, analysis of
covariance models were applied to the change in CHIP-
CE:PRF domain and subdomain T-scores and to the change
in WFIRS-P total and domain scores. The analyses inclu-
ded treatment group as the effect of interest (evaluated at a
significance level of 0.05), the corresponding baseline
score as covariate, and country and age group as blocking
factors. The outputs (based on type III sum of squares)
were the least-squares (LS) mean changes from baseline
for each treatment group and the difference in these LS
means between each drug treatment group and placebo.
Effect sizes were calculated as the difference in LS means
between each active drug and placebo, divided by the root-
mean-square error. Conventionally, effect sizes of 0.2, 0.5
and 0.8 calculated by this method are operationally defined
as small, medium and large, respectively [32]. Results were
analysed using SAS Version 9.1.3 or higher (SAS Insti-
tute Inc., Cary, NC, USA).
3 Results
3.1 Patient Disposition and Baseline Characteristics
As described previously [24], 336 patients were random-
ized (LDX, n = 113; placebo, n = 111; OROS-MPH,
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n = 112) and 196 of these completed the study. Baseline
demographics and disease characteristics were similar
across treatment groups [24]. The full analysis set com-
prised 317 patients (LDX, n = 104; placebo, n = 106;
OROS-MPH, n = 107). The mean age of these patients
was 10.9 years (SD 2.70 years) and 72.2 % were children
(aged B12 years). The number of participants in the full
analysis set who completed the trial were LDX, n = 77;
placebo, n = 42; OROS-MPH, n = 72. The principal
reason for study discontinuation was lack of efficacy,
which was reported in 48.6 % of randomized patients in the
placebo group, 19.6 % in the OROS-MPH group and 9.7 %
in the LDX group [24].
3.2 CHIP-CE:PRF
3.2.1 Baseline T-Scores
At baseline, mean T-scores for all domains and subdomains
were similar across groups (Table 1). The lowest mean
domain T-scores at baseline were almost two population
SDs (i.e. 20 points) below the normative mean (50 points),
and were observed in the Achievement domain (range
30.1–31.2), which was pre-specified as the primary HRQL
outcome in the study. Within the Achievement domain,
mean T-scores were lower in the Academic Performance
subdomain than in the Peer Relations subdomain. Mean T-
scores at baseline were also below 40 (i.e. 1 SD below the
normative mean) for all treatment groups in the Risk
Avoidance, Resilience and Satisfaction domains. In con-
trast, mean Comfort domain T-scores were closer to the
normative mean of 50. The corresponding median T-scores
and ranges are provided in the electronic supplementary
material, Table A.
3.2.2 Placebo-Adjusted Changes at Endpoint
In the LDX treatment group, the change in Achievement
domain T-score from baseline to endpoint was statistically
significantly greater than in the placebo group (effect size
1.280; p \ 0.001) [Fig. 2]. Ranked by decreasing effect
size, statistically significant improvements in T-scores
compared with placebo were also observed in the Risk
Avoidance (1.079; p \ 0.001), Resilience (0.421; p \ 0.01)
and Satisfaction (0.365; p \ 0.05) domains. Within these
domains, there were statistically significant improvements
in all subdomains except Physical Activity and Satisfaction
with Self. Compared with placebo, there were no statisti-
cally significant changes in the Comfort domain or any of its
subdomains in the LDX treatment group (Fig. 2).
Table 1 Mean (SD) CHIP-CE:PRF domain and subdomain T-scores at baseline and endpoint
Baseline Endpoint
LDX Placebo OROS-MPH LDX Placebo OROS-MPH
Achievement 30.9 (9.71) 30.1 (9.37) 31.2 (10.19) 40.3 (10.54) 29.3 (10.06) 37.7 (11.20)
Academic Performance 30.3 (10.18) 29.4 (9.24) 30.5 (9.28) 40.7 (11.24) 28.4 (10.89) 36.9 (11.25)
Peer Relations 38.6 (14.56) 39.2 (11.99) 38.9 (14.00) 42.3 (14.31) 38.9 (12.92) 43.8 (12.61)
Risk Avoidance 34.7 (13.72) 31.6 (11.57) 31.4 (11.59) 44.6 (11.15) 32.8 (12.63) 40.6 (12.08)
Individual Risk Avoidance 41.0 (15.32) 40.2 (12.47) 37.5 (13.76) 49.8 (12.77) 41.6 (14.06) 44.4 (13.47)
Threats to Achievement 34.3 (13.37) 30.6 (11.60) 31.4 (11.16) 43.1 (10.51) 31.8 (11.96) 40.1 (11.62)
Resilience 37.5 (13.16) 36.6 (11.45) 35.5 (11.23) 42.2 (11.43) 37.3 (12.89) 40.1 (12.40)
Family Involvement 40.6 (11.90) 39.7 (11.06) 39.6 (12.03) 42.8 (10.78) 38.2 (13.13) 42.3 (11.72)
Physical Activity 46.0 (13.04) 46.4 (12.33) 46.7 (10.97) 47.2 (11.24) 47.8 (11.92) 47.1 (10.36)
Social Problem-Solving 38.2 (13.45) 36.8 (12.75) 34.5 (12.13) 44.2 (12.33) 38.4 (13.57) 40.8 (14.24)
Satisfaction 35.2 (14.93) 34.4 (14.27) 36.2 (13.82) 39.5 (14.14) 36.1 (13.55) 40.2 (12.99)
Satisfaction with Health 41.2 (13.86) 40.5 (13.66) 41.4 (13.56) 44.2 (12.63) 41.7 (14.42) 43.8 (12.62)
Satisfaction with Self 32.3 (15.75) 31.5 (15.58) 33.9 (13.70) 36.7 (14.94) 33.5 (13.60) 38.6 (12.59)
Comfort 44.0 (12.55) 43.0 (11.77) 44.5 (9.50) 46.8 (12.59) 46.5 (10.44) 48.1 (9.70)
Physical Comfort 50.3 (10.53) 50.9 (10.51) 52.7 (8.82) 52.0 (9.18) 53.6 (8.43) 53.2 (9.34)
Emotional Comfort 39.3 (14.11) 37.2 (12.47) 38.4 (11.31) 42.7 (14.90) 39.7 (12.55) 43.0 (10.83)
Restricted Activity 49.3 (9.93) 48.5 (12.49) 49.0 (10.06) 50.5 (8.51) 52.2 (7.68) 52.0 (7.92)
Domains are shown in bold and subdomains in normal type. Higher scores indicate better health-related quality of life
CHIP-CE:PRF Child Health and Illness Profile-Child Edition: Parent Report Form, LDX lisdexamfetamine dimesylate, OROS-MPH osmotic-
release oral system methylphenidate, SD standard deviation
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In the OROS-MPH reference arm, changes from base-
line to endpoint were also statistically significantly greater
than in the placebo group in the Achievement domain
(effect size 0.912; p \ 0.001) [Fig. 2]. Ranked by
decreasing effect size, statistically significant improve-
ments in T-scores compared with placebo were also
observed in the Risk Avoidance (0.948; p \ 0.001),
Resilience (0.398; p \ 0.05) and Satisfaction (0.349;
p \ 0.05) domains. Within these domains, statistically
significant improvements were observed in all subdo-
mains except Physical Activity and Satisfaction with
Health. Compared with placebo, there were no statisti-
cally significant changes in the Comfort domain or any
of its subdomains in the OROS-MPH reference arm
(Fig. 2).
3.2.3 Changes from Baseline to Week 4, Week 7
and Endpoint
In both active treatment groups, there were statistically
significant improvements from baseline by week 4 in the
Achievement and Risk Avoidance domains, and by week 7
in these and all other domains (Fig. 3).
3.3 WFIRS-P
3.3.1 Baseline Scores
At baseline, mean scores for each of the six WFIRS-P
domains were similar across treatment groups, with the
highest scores (greatest impairment) observed in the
Family domain and the Learning and School domain
(Table 2). The corresponding median scores and ranges
are provided in the electronic supplementary material,
Table B.
3.3.2 Placebo-Adjusted Changes at Endpoint
In the LDX treatment group, the change in WFIRS-P total
score from baseline to endpoint was statistically signifi-
cantly greater than in the placebo group (effect size 0.924;
p \ 0.001) [Fig. 4]. Statistically significant improvements
in scores compared with placebo were observed in the
Learning and School, Family, Social Activities and Risky
Activities domains (p \ 0.001).
In the OROS-MPH reference arm, the change in
WFIRS-P total score from baseline to endpoint was also
statistically significantly greater than in the placebo group
(effect size 0.772; p \ 0.001) [Fig. 4]. Statistically signif-
icant improvements in placebo-adjusted scores were
observed in the same four WFIRS-P domains as for LDX,
and also in the remaining two domains, Life Skills and
Child’s Self-Concept (p \ 0.05).
3.3.3 Changes from Baseline to Week 4, Week 7
and Endpoint
In the LDX group, statistically significant changes from
baseline were observed by week 4 in WFIRS-P total score
and the Learning and School, Social Activities and Risky
LDX OROS-MPH
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Fig. 2 Placebo-adjusted changes in CHIP-CE:PRF domain and sub-
domain T-scores from baseline to endpoint. Histogram shows the LS
mean change from baseline to endpoint in CHIP-CE:PRF domain and
subdomain T-scores for the LDX and OROS-MPH groups after
subtraction of placebo values. Error bars show 95 % confidence
intervals. Effect size is the difference in LS mean divided by root-mean-
square error. Positive differences indicate improvement compared with
placebo. CHIP-CE:PRF Child Health and Illness Profile-Child Edition:
Parent Report Form, LDX lisdexamfetamine dimesylate, LS least-
squares, OROS-MPH osmotic-release oral system methylphenidate.
*p \ 0.05, **p \ 0.01, ***p \ 0.001 vs placebo
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Activities domains, and by week 7 in these and all other
domains (Fig. 5). In the OROS-MPH group, statistically
significant changes from baseline were observed by week 4
in WFIRS-P total score and the Learning and School and
Risky Activities domains, and by week 7 in these and all
other domains (Fig. 5).
4 Discussion
Optimal management of ADHD aims not only to amelio-
rate patients’ symptoms, but also to improve HRQL and to
reduce functional impairment, because these are often the
main motivations for seeking treatment [7, 11]. We have
Table 2 Mean (SD) WFIRS-P domain and total scores at study baseline and endpoint
Baseline Endpoint
LDX Placebo OROS-MPH LDX Placebo OROS-MPH
Family 1.27 (0.731) 1.40 (0.766) 1.40 (0.757) 0.95 (0.760) 1.40 (0.794) 1.07 (0.769)
Learning and School 1.24 (0.647) 1.31 (0.614) 1.23 (0.604) 0.66 (0.512) 1.26 (0.600) 0.82 (0.561)
Life Skills 1.05 (0.475) 1.15 (0.530) 1.09 (0.486) 0.89 (0.541) 1.04 (0.484) 0.88 (0.456)
Child’s Self-Concept 1.05 (0.878) 1.09 (0.781) 1.00 (0.747) 0.83 (0.840) 1.00 (0.825) 0.73 (0.757)
Social Activities 1.02 (0.679) 1.06 (0.613) 1.01 (0.651) 0.76 (0.613) 1.04 (0.662) 0.77 (0.582)
Risky Activities 0.49 (0.379) 0.54 (0.376) 0.59 (0.411) 0.28 (0.319) 0.49 (0.388) 0.41 (0.378)
Total 1.01 (0.454) 1.10 (0.456) 1.07 (0.437) 0.71 (0.450) 1.04 (0.467) 0.79 (0.441)
Higher scores indicate more severe functional impairment
LDX lisdexamfetamine dimesylate, OROS-MPH osmotic-release oral system methylphenidate, SD standard deviation, WFIRS-P Weiss Func-









































































Fig. 3 Changes in CHIP-
CE:PRF domain T-scores from
baseline to study week 4, 7 and
endpoint. Circles indicate the
LS mean change from baseline
in T-scores in the indicated
CHIP-CE:PRF domains for the
a LDX, b OROS-MPH or
c placebo groups. Error bars
show 95 % confidence intervals.
Numbers of observations (n) are
shown for each data point.
Positive differences indicate
improvement compared with
placebo. BL baseline, CHIP-
CE:PRF Child Health and
Illness Profile-Child Edition:





methylphenidate, W4 week 4,
W7 week 7. *p \ 0.05,
**p \ 0.01, ***p \ 0.001 vs
baseline
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previously reported improvements in investigator-rated
ADHD symptoms, measured using the ADHD-RS-IV and
CGI-I instruments, in children and adolescents treated with
LDX in a European, 7-week, phase III trial (SPD489-325)
[24]. The present data show that LDX treatment also
resulted in improvements in HRQL and functioning in this
study, assessed using two parent-rated instruments, the
CHIP-CE:PRF and WFIRS-P, respectively. The reference
treatment, OROS-MPH, also resulted in improvements in
scores on these instruments. In the CHIP-CE:PRF
Achievement domain, which was pre-specified as the pri-
mary HRQL outcome, both LDX and OROS-MPH sig-
nificantly improved mean T-scores versus placebo, with
large effect sizes (1.280 and 0.912, respectively). Based on
these data, the Summary of Product Characteristics, part of
the European marketing authorization recently approved
under the decentralized procedure, notes that LDX
‘‘showed significant improvement in child achievement in
academic performance’’.
This is the first study of any stimulant treatment for
ADHD to use the CHIP-CE:PRF. The reliability and
validity of this generic, paediatric HRQL instrument in
ADHD have been established in the prospective, pan-
European ADORE (Attention Deficit Hyperactivity Dis-
order Observational Research in Europe) study, which
included 1477 children and adolescents with ADHD in the
analysis [25], and have been confirmed in a combined
analysis [33] of baseline data from 794 patients aged
6–15 years in five atomoxetine trials [33–37]. Baseline
CHIP-CE:PRF values in the present study were similar to
values reported in both of these analyses: mean T-scores in
the Achievement and Risk Avoidance domains were
approximately 2 population SDs (20 points) below the US
community normative mean (50 points); those in the
Resilience and Satisfaction domains were at least 1 SD
below the normative mean; and the mean T-score in the
Comfort domain was within 1 SD of the normative mean.
Together, the results of these studies indicate that untreated
ADHD imposes a substantial burden of illness. This is
reflected by substantial economic costs of the disorder to
society [38]. By comparison, in other studies using the
CHIP in patient populations, mean standardized domain or
subdomain T-scores were 1 SD or more below the nor-
mative mean in children undergoing the last phase of
maintenance therapy for leukaemia [39], but were within 1
SD of the normative mean in children and/or adolescents
with chronic kidney disease [40–43] or asthma [44, 45].
The impact of LDX treatment was greatest in the
Achievement domain of the CHIP-CE:PRF (effect size
1.280). Factor analyses of both the ADORE and combined
atomoxetine study data have suggested that, unlike the
subdomains of the other four CHIP-CE:PRF domains, the
Academic Performance and Peer Relations subdomains of
Achievement are distinct constructs in patients with ADHD
[25, 33]. This may explain the difference between the
effect sizes for LDX treatment observed in these subdo-
mains (1.222 and 0.562, respectively). A robust treatment
effect of LDX was also observed in the Risk Avoidance
domain (effect size 1.079). Statistically significant placebo-
adjusted LDX treatment effects were observed in the
Resilience and Satisfaction domains, but not in the Comfort
domain. At endpoint, mean T-scores for all CHIP-CE:PRF
domains in the LDX treatment group were within
approximately 1 SD of the normative mean. A similar
pattern was observed in the OROS-MPH reference arm.
Thus, in both active treatment arms, the greatest impact of
stimulant pharmacotherapy was observed in the domains
with the most profound deficits at baseline.
Improved HRQL in LDX-treated adults with ADHD
was previously documented in a 4-week, open-label study
employing the ADHD Impact Module for Adults. Meth-
ylphenidate and mixed amfetamine salts have also been
reported to have a beneficial impact on HRQL measured
using other instruments [8, 9]. The non-stimulant ato-
moxetine is the only other ADHD pharmacotherapy for
which the impact on HRQL has been investigated using
CHIP-CE:PRF. A meta-analysis of atomoxetine studies
[46] indicated that treatment benefits were most pro-
nounced in the Achievement and Risk Avoidance domains,
LDX OROS-MPH
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Fig. 4 Placebo-adjusted changes in WFIRS-P domain and total
scores from baseline to endpoint. Histogram shows the LS mean
change from baseline to endpoint in WFIRS-P domain and total
scores for the LDX and OROS-MPH groups after subtraction of
placebo values. Error bars show 95 % confidence intervals. Effect
size is the difference in LS mean divided by root-mean-square error.
Negative differences indicate improvement compared with placebo.
LDX lisdexamfetamine dimesylate, LS least-squares, OROS-MPH
osmotic-release oral system methylphenidate, WFIRS-P Weiss Func-
tional Impairment Ratings Scale-Parent Report. *p \ 0.05,
***p \ 0.001 vs placebo
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as in the present study. The effect sizes for atomoxetine in
these domains (0.431 and 0.489, respectively, [46]) were,
however, somewhat smaller than those reported here for
both LDX and OROS-MPH. Furthermore, unlike the
stimulants investigated in the present study, atomoxetine
did not statistically significantly affect scores in the Satis-
faction and Resilience domains. These results suggest that
earlier observations that stimulants are more effective than
non-stimulants in reducing the symptoms of ADHD [47]
may extend to HRQL deficits, at least as measured using
the CHIP-CE:PRF.
The WFIRS-P was designed to provide a more sensitive
and meaningful measure of functional impairment in
patients with ADHD than that provided by generic instru-
ments. The instrument can also be used to define impair-
ment for clinical diagnostic purposes. As an outcome
measure, it also has good internal consistency and sensi-
tivity to change, as well as moderate convergent validity
with other instruments [30]. However, published data for
the WFIRS-P are limited [26, 27] and there are currently no
published population norm data [30]. In the present study,
mean WFIRS-P total scores at baseline were approximately
1.0 on the Likert scale (which has a range of 0–3).
Although this could be interpreted as modest impairment, it
is important to note that these mean responses at the
domain or total level do not capture dispersion, and are
likely to conceal high individual item scores of potential
clinical significance. The mean total scores at baseline
exceed the optimal cut-off score (0.65) for differentiating
children with and without ADHD, as derived by receiver-
operating characteristics curve analysis in a multicentre,
observational study (Hodgkins P, et al., personal commu-
nication). The effect sizes for placebo-adjusted changes
from baseline to endpoint in WFIRS-P total score suggest
that both active treatment effects were robust (LDX, 0.924;
OROS-MPH, 0.772). As at baseline, the use of mean scores
may not fully reflect treatment-induced improvements at


















































































































Fig. 5 Change in WFIRS-P scores from baseline to study week 4, 7
and endpoint. Circles indicate the LS mean change from baseline in
scores in the indicated WFIRS-P domain or total scores for a LDX,
b OROS-MPH or c placebo groups. Error bars show 95 % confidence
intervals. Numbers of observations (n) are shown for each data point.
Negative differences indicate improvement compared with placebo.
BL baseline, EP endpoint, LDX lisdexamfetamine dimesylate, LS
least-squares, OROS-MPH osmotic-release oral system methylpheni-
date, W4 week 4, W7 week 7, WFIRS-P Weiss Functional Impairment
Ratings Scale-Parent Report. *p \ 0.05, **p \ 0.01, ***p \ 0.001
vs baseline
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CHIP-CE:PRF results, effect sizes were greatest in the
WFIRS-P domains that were most impaired at baseline.
The interdependence of symptom severity, functioning
and HRQL in ADHD is still uncertain and under explora-
tion [9]. A combined analysis of atomoxetine clinical trials
found that correlations between CHIP-CE:PRF T-scores
(total, domain and subdomain) and ADHD-RS-IV total
score were low (mostly below 0.4) [33]. Correlative anal-
yses of the relevant outcome measures from the present
study are awaited. However, effect sizes at endpoint were
larger for ADHD-RS-IV total score (LDX, 1.80; OROS-
MPH, 1.26) [24] than for any domain of the CHIP-CE:PRF
or WFIRS-P, supporting the notion that symptoms and
HRQL or functioning are distinct, but related, constructs
[48]. Furthermore, while symptomatic benefits were evi-
dent as early as study week 1 [24], some CHIP-CE:PRF
and WFIRS-P domains did not show improvements until
study week 7, suggesting that some aspects of HRQL and
functioning may respond to stimulant medications over a
longer treatment period than others. Also warranting fur-
ther investigation, although modest and awaiting post hoc
statistical analysis, are the differences between the two
active treatments in effect sizes observed in some CHIP-
CE:PRF and WFIRS-P domains, which may have impli-
cations for individualized treatment [10].
The strengths of this study include its randomized,
double-blind, placebo-controlled design, and the enrolment
of both children and adolescents at multiple centres in
Europe. Five principal limitations of the study design
should, however, be considered when interpreting these
results. First, the study population was enrolled according
to stringent inclusion and exclusion criteria and so may not
be typical of patients seen in general clinical practice.
Second, dose optimization was designed to achieve bal-
anced efficacy and tolerability, but precluded evaluation of
whether the stimulant treatment effects were dose depen-
dent and whether the LDX and OROS-MPH doses were
equivalent. Third, the study was not designed or powered
for direct comparison of the test drug (LDX) with the
active control (OROS-MPH). Fourth, the short-term nature
of the study does not permit evaluation of the long-term
impact of LDX or OROS-MPH treatment on HRQL and
functional outcomes. The results of SPD489-326, a follow-
on study (with additional US patients) comprising open-
label LDX treatment for at least 26 weeks, coupled to a
subsequent 6-week, double-blind, parallel-group, placebo-
controlled, randomized-withdrawal period, may provide
insight in this regard. Finally, the majority of patients in the
LDX and OROS-MPH groups completed the study, but the
majority of patients in the placebo group left the study
early.
The HRQL and functional impairment instruments
selected for this study also present their own strengths and
weaknesses. Parental proxy assessments overcome the
issue of potentially unreliable self-rating by patients with
ADHD, especially younger children, but may capture dif-
ferent aspects of HRQL and functioning compared with
self-rated instruments. For consistency, participants of all
ages were assessed using the same questionnaires, despite
the availability of self-rated versions of the instruments for
adolescents. The CHIP-CE:PRF T-scores are generated
using algorithms based on a US reference population, and
although the Spanish CHIP-CE:PRF reference population
is very similar [49, 50], these community samples may not
be representative of normative HRQL in Europe.
5 Conclusions
Once-daily, optimized doses of LDX and OROS-MPH
were more effective than placebo in improving HRQL and
functioning in children and adolescents with at least
moderately symptomatic ADHD in this European, 7-week,
phase III study. The effects were seen across multiple
domains of the CHIP-CE:PRF and WFIRS-P instruments,
including the key domains relating to achievement in
school.
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